Patient Characteristics
| Patient characteristic | Value* |
| Age (y) | |
| Median | 75.5 |
| Range | 57–85 |
| Gleason score | |
| Median | 8 |
| No. of patients with Gleason score of: | |
| <7 | 2 |
| 7 | 6 |
| 8 | 2 |
| 9 | 6 |
| Unknown | 5 |
| PSA (ng/mL) | |
| Median | 502 |
| Range | 6–1,855 |
| Alkaline phosphatase (U/L) | |
| Mean | 166.8 |
| SD | 121.8 |
| Localization of metastases | |
| Lymph node(s) | 9 |
| Bone | 21 |
| Liver | 1 |
| Lung | 5 |
| Brain | 1 |
| Other | 2 |
| Local recurrence | 1 |
| Previous therapy | |
| RPx | 10 |
| LRTx | 13 |
| CRPC | 21 |
| Abiraterone (Zytiga; Janssen Biotech, Inc.) | 17 |
| Enzalutamide (Xtandi; Astellas Pharma Inc.) | 12 |
| Zoledronic acid (Zometa; Novartis)/denosumab (Xgeva; Amgen Inc.) | 8 |
| 223RaCl2 (Xofigo; Bayer) | 9 |
| CTx | 13 |
↵* Values are reported as numbers of patients unless otherwise indicated.
RPx = radical prostatectomy; LRTx = local radiation therapy; CRPC = castration-resistant prostate cancer; CTx = chemotherapy.